Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone in Psychotic Adolescents
NCT00421954Phase 3Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- May 2006
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ziprasidone in schizophreniform disorder, schizoaffective disorder, psychosis and 2 more, sponsored by New York State Psychiatric Institute. Primary endpoints: Weight Gain at 7 weeks and Adverse Events at 7 weeks. Started May 2006; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophreniform disorderschizoaffective disorderpsychosismajor depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00421954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421954.